The use of MR‑less MNI based neuronavigation for 10 Hz rTMS depression therapy: electrophysiological and clinical implications.

Repetitive transcranial magnetic stimulation (rTMS) is a popular and effective treatment for drug resistant depression. However, there is considerable variability in clinical outcomes, in previous studies and between patients. Because of high requirements for the use of fMRI based neuronavigation, many practitioners of rTMS still choose to use a standard 5 cm rule for rTMS coil placement which leads to large variations in which brain regions are being stimulated.

Pathological Imitative Behavior and Response Preparation in Schizophrenia.

Introduction: Pathological imitative behavior (ehopraxia) is occasionally observed in schizophrenia patients. However, only a severe form of echopraxia can be detected with the help of a direct observation. Therefore, our goal was to study a latent form of pathological imitative behavior in this disorder, which is indicated by an increase of imitative tendencies.

Response preparation and intra-individual reaction time variability in schizophrenia.

It is important to prepare response in advance to increase the efficiency of its execution. The process of response preparation is usually studied using the precueing paradigm. In this paradigm subjects have to employ the preceding information about further imperative stimulus to perform proper response preparation, which shortens the reaction time of subsequent response execution.

Electrophysiological differences between high and low frequency rTMS protocols in depression treatment.

Repetitive transcranial magnetic stimulation (rTMS) is a rapidly expanding mean in drug resistant depression treatment. Yet, despite vast research in this field, exact neurophysiological mechanism of rTMS therapy still remains unclear. This results in difficulties choosing suitable rTMS parameters in advance and compromises thorough evaluation of efficacy after the treatment.

Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.

This postauthorization safety study evaluated the long-term safety, tolerability, and efficacy of risperidone long-acting injectable (RLAI) in routine clinical practice. In this 6-month, multicenter, European, naturalistic study, patients were included if, during routine clinical practice, long-term antipsychotic therapy with RLAI was deemed necessary by the treating physician. Efficacy measures included Clinical Global Impression-Severity and Global Assessment of Functioning.

Effects of risperidone on auditory information processing in neuroleptic-naive patients with schizophrenia spectrum disorders.

Early effects of risperidone (2.5 +/- 1 mg/day) on auditory information processing were investigated in 9 neuroleptic naive patients with schizophrenia spectrum disorders and 9 healthy controls by using event-related potentials (ERPs). ERPs were elicited during active auditory "oddball" paradigm and were recorded before and after two weeks of treatment.

Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.

We investigated effects of olanzapine (5-10 mg/day) on passive and active attention in 11 patients with schizophrenia spectrum disorders and 15 healthy controls by using auditory evoked potentials (AEPs) mismatch negativity (MMN) and P300. AEPs were elicited during active and passive auditory "oddball" paradigms before, after 2 weeks and 4 weeks of olanzapine treatment. Baseline P300 amplitudes, but not MMN, were significantly reduced in patients compared with controls.